Meisoindigo
Based on 2 publication(s) in Google Scholar
Meisoindigo (Dian III), a derivative of Indirubin (HY-N0117), halts the cell cycle at the G0/G1 phase and induces apoptosis in primary acute myeloid leukemia (AML) cells. Meisoindigo exhibits high antitumor activity.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 99.91%
- No. CAS: 97207-47-1
- Fòrmula: C17H12N2O2
- Peso molecular:276.29
-
Almacenamiento:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
Publications Citing Use of MedChemExpress (MCE) Meisoindigo
More
Actividad biológica
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A2780 | IC50 |
6.57 μM
Compound: Mei
|
Cytotoxicity against human A2780 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity against human A2780 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 38634707] |
| A549 | IC50 |
57.3 μM
Compound: 6a, MIO, Meisoindigo
|
Cytotoxicity against human A549 cells after 48 hrs by SRB assay
Cytotoxicity against human A549 cells after 48 hrs by SRB assay
|
[PMID: 25151579] |
| COLO 205 | IC50 |
7.55 μM
Compound: Mei
|
Cytotoxicity against human COLO 205 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity against human COLO 205 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 38634707] |
| HCT-116 | IC50 |
15.4 μM
Compound: 2
|
Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
|
[PMID: 19783149] |
| HCT-116 | IC50 |
27 μM
Compound: 6a, MIO, Meisoindigo
|
Cytotoxicity against human HCT116 cells after 48 hrs by SRB assay
Cytotoxicity against human HCT116 cells after 48 hrs by SRB assay
|
[PMID: 25151579] |
| HCT-116 | IC50 |
5.36 μM
Compound: Mei
|
Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 38634707] |
| HeLa | IC50 |
15.7 μM
Compound: 6a, MIO, Meisoindigo
|
Cytotoxicity against human HeLa cells after 48 hrs by SRB assay
Cytotoxicity against human HeLa cells after 48 hrs by SRB assay
|
[PMID: 25151579] |
| HL-60 | IC50 |
12.2 μM
Compound: 2
|
Antiproliferative activity against human HL60 cells after 5 days by MTT assay
Antiproliferative activity against human HL60 cells after 5 days by MTT assay
|
[PMID: 19783149] |
| Huh-7 | IC50 |
18.3 μM
Compound: 2
|
Antiproliferative activity against human HuH7 cells after 72 hrs by MTT assay
Antiproliferative activity against human HuH7 cells after 72 hrs by MTT assay
|
[PMID: 19783149] |
| IMR-90 | IC50 |
7.7 μM
Compound: 2
|
Antiproliferative activity against human IMR90 cells after 72 hrs by MTT assay
Antiproliferative activity against human IMR90 cells after 72 hrs by MTT assay
|
[PMID: 19783149] |
| K562 | IC50 |
23.3 μM
Compound: 6a, MIO, Meisoindigo
|
Cytotoxicity against human K562 cells after 48 hrs by SRB assay
Cytotoxicity against human K562 cells after 48 hrs by SRB assay
|
[PMID: 25151579] |
| K562 | IC50 |
6.7 μM
Compound: 2
|
Antiproliferative activity against human K562 cells after 72 hrs by MTT assay
Antiproliferative activity against human K562 cells after 72 hrs by MTT assay
|
[PMID: 19783149] |
| K562 | IC50 |
8.17 μM
Compound: Mei
|
Cytotoxicity against human K562 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity against human K562 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 38634707] |
| L1210 | IC50 |
167 μM
Compound: 6a, MIO, Meisoindigo
|
Cytotoxicity against mouse L1210 cells after 48 hrs by SRB assay
Cytotoxicity against mouse L1210 cells after 48 hrs by SRB assay
|
[PMID: 25151579] |
| LoVo | IC50 |
12.67 μM
Compound: Mei
|
Cytotoxicity against human LoVo cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity against human LoVo cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 38634707] |
| MGC-803 | IC50 |
128 μM
Compound: 6a, MIO, Meisoindigo
|
Cytotoxicity against human MGC803 cells after 48 hrs by SRB assay
Cytotoxicity against human MGC803 cells after 48 hrs by SRB assay
|
[PMID: 25151579] |
| NCI-H358 | IC50 |
>20 μM
Compound: Mei
|
Cytotoxicity against human NCI-H358 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity against human NCI-H358 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 38634707] |
| RKO | IC50 |
11.63 μM
Compound: Mei
|
Cytotoxicity against human RKO cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity against human RKO cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 38634707] |
| SW13 | IC50 |
12.89 μM
Compound: Mei
|
Cytotoxicity against human SW13 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity against human SW13 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 38634707] |
| SW480 | IC50 |
2.8 μM
Compound: Mei
|
Cytotoxicity against human SW480 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity against human SW480 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 38634707] |
| SW-620 | IC50 |
9.14 μM
Compound: Mei
|
Cytotoxicity against human SW620 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity against human SW620 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 38634707] |
Meisoindigo (Dian III; 5-20 μM; for 24?hours) inhibits growth of the AML cell lines[1].
Meisoindigo (10?μM; for 24?hours) induces apoptosis of acute myeloid leukemia[1].
Meisoindigo (5-10?μM; for 24?hours) causes cell-cycle arrest[1].
Meisoindigo (5-10?μM; for 24?hours) increases the cleaved caspase-3 and pro-apoptotic Bak, and decreases Bcl-2 and Bcl-xL levels in HL-60 cells[1].
Meisoindigo (10, 30, 50, 100, 150 μM; 24 hours) interdicts LPS-induced (1 μg/mL) NLRP3 inflammasome activation and M1/M2 polarization through down-regulation of TLR4 pathways after OGD/R in HT-22 and BV2 cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HL-60, NB4, U937 leukemic cell lines
-
Concentration:5, 10, 15, 20 μM
-
Incubation Time:For 24 hours
-
Result:Inhibited growth of the AML cell lines in a dose- and time-dependent manner.
-
Cell Line:HL-60 cells
-
Concentration:10 μM
-
Incubation Time:For 24 hours
-
Result:Induced apoptosis of acute myeloid leukemia.
-
Cell Line:HL-60 cells
-
Concentration:5, 10 μM
-
Incubation Time:For 24 hours
-
Result:Caused cell-cycle arrest, with more cells in sub-G1 and G0/G1 phases and fewer cells in the S phase, in a dose-dependent manner.
-
Cell Line:HL-60 cells
-
Concentration:5, 10 μM
-
Incubation Time:For 24 hours
-
Result:Increased the cleaved caspase-3 and pro-apoptotic Bak, and decreased Bcl-2 and Bcl-xL levels in HL-60 cells.
Meisoindigo (2, 4, 8, 12 mg/kg; IP; before MCAO and 2 h after reperfusion) significantly reduces infarct volume, ameliorates neurological deficits 3 days after middle cerebral artery occlusion (MCAO) in Wild-type C57BL/6J mice (25-30 g). Meisoindigo reduces edema and lowers AQP4 expression in the brain[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:NOD/SCID mice, 6-8 weeks old, with HL-60 leukemic cells[1]
-
Dosage:50, 100, 150 mg/kg
-
Administration:IP; daily; for 14 days
-
Result:Had anti-leukemic activity in vivo.
Chemical Information
-
No. CAS 97207-47-1
-
Appearance Solid
-
Peso molecular 276.29
-
Fòrmula C17H12N2O2
-
Color Grayish brown to reddish brown
-
SMILES
O=C1N(C)C2=C(C=CC=C2)/C1=C3C(NC4=C\3C=CC=C4)=O
-
Synonyms
Dian III; N-Methylisoindigotin; Natura-α
-
Structure Classification
-
Initial Source
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Cancer Res
Single-Cell Lineage Tracing Uncovers Resistance Signatures and Sensitizing Strategies to FLT3 Inhibitors in Acute Myeloid Leukemia. [Abstract]2025 Nov 21:10.1158/0008-5472.CAN-24-3753. PMID: 41270153 -
Solvente y solubilidad
DMSO : ≥ 51 mg/mL (184.59 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (9.05 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureza y Documentación
-
Ficha de datos (286 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Lee CC, et al. Meisoindigo is a promising agent with in vitro and in vivo activity against human acute myeloid leukemia. Leuk Lymphoma. 2010 May;51(5):897-905. [Content Brief]
[2]. Yingze Ye, et al. Meisoindigo Protects Against Focal Cerebral Ischemia-Reperfusion Injury by Inhibiting NLRP3 Inflammasome Activation and Regulating Microglia/Macrophage Polarization via TLR4/NF-κB Signaling Pathway. Front Cell Neurosci. 2019 Dec 16;13:553. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.6194 mL | 18.0969 mL | 36.1939 mL | 90.4846 mL |
| 5 mM | 0.7239 mL | 3.6194 mL | 7.2388 mL | 18.0969 mL | |
| 10 mM | 0.3619 mL | 1.8097 mL | 3.6194 mL | 9.0485 mL | |
| 15 mM | 0.2413 mL | 1.2065 mL | 2.4129 mL | 6.0323 mL | |
| 20 mM | 0.1810 mL | 0.9048 mL | 1.8097 mL | 4.5242 mL | |
| 25 mM | 0.1448 mL | 0.7239 mL | 1.4478 mL | 3.6194 mL | |
| 30 mM | 0.1206 mL | 0.6032 mL | 1.2065 mL | 3.0162 mL | |
| 40 mM | 0.0905 mL | 0.4524 mL | 0.9048 mL | 2.2621 mL | |
| 50 mM | 0.0724 mL | 0.3619 mL | 0.7239 mL | 1.8097 mL | |
| 60 mM | 0.0603 mL | 0.3016 mL | 0.6032 mL | 1.5081 mL | |
| 80 mM | 0.0452 mL | 0.2262 mL | 0.4524 mL | 1.1311 mL | |
| 100 mM | 0.0362 mL | 0.1810 mL | 0.3619 mL | 0.9048 mL |